Competitive regulation of hepcidin mRNA by soluble and...

Details Competitive regulation of hepcidin mRNA by soluble and... Competitive regulation of hepcidin mRNA by soluble and...

2009-03-04

2010-06-29

Monshipouri, Maryam (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S006120

Reexamination Certificate

active

07745407

ABSTRACT:
Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.

REFERENCES:
patent: 2006/0073497 (2006-04-01), Goldberg et al.
patent: 2007/0166711 (2007-07-01), Samuels et al.
patent: 2004092405 (2004-10-01), None
George Papanikolaou et al., “Mutations in HFE2 Cause Iron Overload in Chromosome 1q-linked Juvenile Hemochromatosis”, Nature Genetics Advance Online Publication, 2003 Nature Publishing Group; http://www.nature.com
aturegenetics, pp. 1-6.
George Papanikolaou et al., “Hepcidin in Iron Overload Disorders”, Blood, May 15, 2005, No. 10, pp. 4103-4105.

Affiliated with

Also associated with

Rating

Competitive regulation of hepcidin mRNA by soluble and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Competitive regulation of hepcidin mRNA by soluble and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Competitive regulation of hepcidin mRNA by soluble and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4155496